Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marizomib and Bevacizumab in Recurrent Glioblastoma
NCT02330562Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2015
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of marizomib in malignant glioma and glioblastoma (GBM) (5 arms), sponsored by Celgene Corporation. Primary endpoints: Radiographic Objective Response Rate up to 48 weeks and Overall Survival up to 42 weeks. Started Apr 2015; status: completed.
02
Drugs
marizomib
03
Conditions
malignant gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT02330562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02330562.